Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Flower isoforms promote competitive growth in cancer.

Madan E, Pelham CJ, Nagane M, Parker TM, Canas-Marques R, Fazio K, Shaik K, Yuan Y, Henriques V, Galzerano A, Yamashita T, Pinto MAF, Palma AM, Camacho D, Vieira A, Soldini D, Nakshatri H, Post SR, Rhiner C, Yamashita H, Accardi D, Hansen LA, Carvalho C, Beltran AL, Kuppusamy P, Gogna R, Moreno E.

Nature. 2019 Aug;572(7768):260-264. doi: 10.1038/s41586-019-1429-3. Epub 2019 Jul 24.

PMID:
31341286
2.

Cell competition in tumor evolution and heterogeneity: Merging past and present.

Pelham CJ, Nagane M, Madan E.

Semin Cancer Biol. 2019 Jul 16. pii: S1044-579X(19)30071-9. doi: 10.1016/j.semcancer.2019.07.008. [Epub ahead of print] Review.

PMID:
31323289
3.

Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.

Takami H, Fukushima S, Aoki K, Satomi K, Narumi K, Hama N, Matsushita Y, Fukuoka K, Yamasaki K, Nakamura T, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T, Ueki K, Narita Y, Shibui S, Totoki Y, Shibata T, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K; Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium).

Neuropathol Appl Neurobiol. 2019 Jun 10. doi: 10.1111/nan.12570. [Epub ahead of print]

PMID:
31179566
4.

Publisher Correction: DNA demethylation is associated with malignant progression of lower-grade gliomas.

Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A.

Sci Rep. 2019 May 23;9(1):7935. doi: 10.1038/s41598-019-43790-7.

5.

Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.

Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, Takayanagi S, Hana T, Takahashi S, Kitagawa Y, Koike T, Kobayashi Y, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Narita Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Mukasa A, Saito N, Kakimi K.

Cancer Immunol Res. 2019 Jul;7(7):1148-1161. doi: 10.1158/2326-6066.CIR-18-0599. Epub 2019 May 14.

PMID:
31088845
6.

Detailed standardized protocol to prevent cerebrospinal fluid shunt infection.

Okamura Y, Maruyama K, Fukuda S, Horikawa H, Sasaki N, Noguchi A, Nagane M, Shiokawa Y.

J Neurosurg. 2019 Feb 15:1-5. doi: 10.3171/2018.10.JNS181432. [Epub ahead of print]

PMID:
30771771
7.

DNA demethylation is associated with malignant progression of lower-grade gliomas.

Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A.

Sci Rep. 2019 Feb 13;9(1):1903. doi: 10.1038/s41598-019-38510-0. Erratum in: Sci Rep. 2019 May 23;9(1):7935.

8.

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.

Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, Kato M, Honda-Kitahara M, Ichikawa H, Kohno T, Sasaki A, Hirato J, Hirose T, Komori T, Satomi K, Yoshida A, Yamasaki K, Nakano Y, Takada A, Nakamura T, Takami H, Matsushita Y, Suzuki T, Nakamura H, Makino K, Sonoda Y, Saito R, Tominaga T, Matsusaka Y, Kobayashi K, Nagane M, Furuta T, Nakada M, Narita Y, Hirose Y, Ohba S, Wada A, Shimizu K, Kurozumi K, Date I, Fukai J, Miyairi Y, Kagawa N, Kawamura A, Yoshida M, Nishida N, Wataya T, Yamaoka M, Tsuyuguchi N, Uda T, Takahashi M, Nakano Y, Akai T, Izumoto S, Nonaka M, Yoshifuji K, Kodama Y, Mano M, Ozawa T, Ramaswamy V, Taylor MD, Ushijima T, Shibui S, Yamasaki M, Arai H, Sakamoto H, Nishikawa R, Ichimura K; Japan Pediatric Molecular Neuro-Oncology Group (JPMNG).

Acta Neuropathol Commun. 2018 Dec 4;6(1):134. doi: 10.1186/s40478-018-0630-1.

9.

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M.

Neuro Oncol. 2019 Feb 19;21(3):348-359. doi: 10.1093/neuonc/noy200.

PMID:
30500939
10.

Demonstration of Mitochondrial Damage and Mitophagy in Cisplatin-Mediated Nephrotoxicity.

Ichinomiya M, Shimada A, Ohta N, Inouchi E, Ogihara K, Naya Y, Nagane M, Morita T, Satoh M.

Tohoku J Exp Med. 2018 Sep;246(1):1-8. doi: 10.1620/tjem.246.1.

11.

Hepatosplenic γδ T Cell Lymphoma Involving the Brain.

Iijima S, Chiba T, Maruyama K, Saito K, Kobayashi K, Yamagishi Y, Shibahara J, Takayama N, Shiokawa Y, Nagane M.

World Neurosurg. 2018 Oct;118:139-142. doi: 10.1016/j.wneu.2018.07.048. Epub 2018 Jul 18.

PMID:
30030187
12.

Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial.

Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, Arakawa Y, Miyamoto S, Beppu T, Sugiyama K, Nakamura H, Nagane M, Nakasu Y, Hashimoto N, Terasaki M, Matsumura A, Ishikawa E, Wakabayashi T, Iwadate Y, Ohue S, Kobayashi H, Kinoshita M, Asano K, Mukasa A, Tanaka K, Asai A, Nakamura H, Abe T, Muragaki Y, Iwasaki K, Aoki T, Watanabe T, Sasaki H, Izumoto S, Mizoguchi M, Matsuo T, Takeshima H, Hayashi M, Jokura H, Mizowaki T, Shimizu E, Shirato H, Tago M, Katayama H, Fukuda H, Shibui S; Japan Clinical Oncology Group.

J Clin Oncol. 2018 Jun 20:JCO2018786186. doi: 10.1200/JCO.2018.78.6186. [Epub ahead of print]

PMID:
29924704
13.

Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.

Nagane M, Kanai E, Shibata Y, Shimizu T, Yoshioka C, Maruo T, Yamashita T.

PLoS One. 2018 Apr 12;13(4):e0195151. doi: 10.1371/journal.pone.0195151. eCollection 2018.

14.

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.

Wakabayashi T, Natsume A, Mizusawa J, Katayama H, Fukuda H, Sumi M, Nishikawa R, Narita Y, Muragaki Y, Maruyama T, Ito T, Beppu T, Nakamura H, Kayama T, Sato S, Nagane M, Mishima K, Nakasu Y, Kurisu K, Yamasaki F, Sugiyama K, Onishi T, Iwadate Y, Terasaki M, Kobayashi H, Matsumura A, Ishikawa E, Sasaki H, Mukasa A, Matsuo T, Hirano H, Kumabe T, Shinoura N, Hashimoto N, Aoki T, Asai A, Abe T, Yoshino A, Arakawa Y, Asano K, Yoshimoto K, Shibui S; Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG).

J Neurooncol. 2018 Jul;138(3):627-636. doi: 10.1007/s11060-018-2831-7. Epub 2018 Mar 20.

15.

Ataxia-Telangiectasia Mutated (ATM) Kinase Regulates eNOS Expression and Modulates Radiosensitivity in Endothelial Cells Exposed to Ionizing Radiation.

Nagane M, Kuppusamy ML, An J, Mast JM, Gogna R, Yasui H, Yamamori T, Inanami O, Kuppusamy P.

Radiat Res. 2018 May;189(5):519-528. doi: 10.1667/RR14781.1. Epub 2018 Feb 23.

PMID:
29474156
16.

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Madan E, Parker TM, Bauer MR, Dhiman A, Pelham CJ, Nagane M, Kuppusamy ML, Holmes M, Holmes TR, Shaik K, Shee K, Kiparoidze S, Smith SD, Park YA, Gomm JJ, Jones LJ, Tomás AR, Cunha AC, Selvendiran K, Hansen LA, Fersht AR, Hideg K, Gogna R, Kuppusamy P.

J Biol Chem. 2018 Mar 23;293(12):4262-4276. doi: 10.1074/jbc.RA117.000950. Epub 2018 Jan 30.

17.

Smart Glasses for Neurosurgical Navigation by Augmented Reality.

Maruyama K, Watanabe E, Kin T, Saito K, Kumakiri A, Noguchi A, Nagane M, Shiokawa Y.

Oper Neurosurg (Hagerstown). 2018 Nov 1;15(5):551-556. doi: 10.1093/ons/opx279.

PMID:
29373710
18.

MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.

Takano S, Hattori K, Ishikawa E, Narita Y, Iwadate Y, Yamaguchi F, Nagane M, Akimoto J, Oka H, Tanaka S, Sakata M, Matsuda M, Yamamoto T, Chiba S, Matsumura A.

World Neurosurg. 2018 Apr;112:e69-e73. doi: 10.1016/j.wneu.2017.12.028. Epub 2017 Dec 16.

PMID:
29258950
19.

Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.

Lee J, Shishido-Hara Y, Suzuki K, Shimizu S, Kobayashi K, Kamma H, Shiokawa Y, Nagane M.

Jpn J Clin Oncol. 2017 Oct 1;47(10):925-934. doi: 10.1093/jjco/hyx098.

PMID:
28981733
20.

Distinct molecular profile of diffuse cerebellar gliomas.

Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Suzuki T, Otani R, Kobayashi K, Maruyama T, Tanaka S, Takayanagi S, Nejo T, Takahashi S, Ichimura K, Nakamura T, Muragaki Y, Narita Y, Nagane M, Ueki K, Nishikawa R, Shibahara J, Aburatani H, Saito N.

Acta Neuropathol. 2017 Dec;134(6):941-956. doi: 10.1007/s00401-017-1771-1. Epub 2017 Aug 29.

21.

Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.

Wang W, Zhang H, Liu S, Kim CK, Xu Y, Hurley LA, Nishikawa R, Nagane M, Hu B, Stegh AH, Cheng SY, Cheng C.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8366-8371. doi: 10.1073/pnas.1701289114. Epub 2017 Jul 17.

22.

Genetic and epigenetic stability of oligodendrogliomas at recurrence.

Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T, Tanaka S, Takayanagi S, Yanagisawa S, Nejo T, Takahashi S, Omata M, Otani R, Saito K, Narita Y, Nagane M, Nishikawa R, Ueki K, Aburatani H, Saito N.

Acta Neuropathol Commun. 2017 Mar 7;5(1):18. doi: 10.1186/s40478-017-0422-z.

23.

Lipophilic triphenylphosphonium derivatives enhance radiation-induced cell killing via inhibition of mitochondrial energy metabolism in tumor cells.

Yasui H, Yamamoto K, Suzuki M, Sakai Y, Bo T, Nagane M, Nishimura E, Yamamori T, Yamasaki T, Yamada KI, Inanami O.

Cancer Lett. 2017 Apr 1;390:160-167. doi: 10.1016/j.canlet.2017.01.006. Epub 2017 Jan 16.

24.

Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas.

Fukushima S, Yamashita S, Kobayashi H, Takami H, Fukuoka K, Nakamura T, Yamasaki K, Matsushita Y, Nakamura H, Totoki Y, Kato M, Suzuki T, Mishima K, Yanagisawa T, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Nagane M, Iuchi T, Yoshimoto K, Mizoguchi M, Tamura K, Sakai K, Sugiyama K, Nakada M, Yokogami K, Takeshima H, Kanemura Y, Matsuda M, Matsumura A, Kurozumi K, Ueki K, Nonaka M, Asai A, Kawahara N, Hirose Y, Takayama T, Nakazato Y, Narita Y, Shibata T, Matsutani M, Ushijima T, Nishikawa R, Ichimura K; Intracranial Germ Cell Tumor Genome Analysis Consortium (The iGCTConsortium).

Acta Neuropathol. 2017 Mar;133(3):445-462. doi: 10.1007/s00401-017-1673-2. Epub 2017 Jan 11.

PMID:
28078450
25.

Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma.

Nakamura T, Yamashita S, Fukumura K, Nakabayashi J, Tanaka K, Tamura K, Tateishi K, Kinoshita M, Fukushima S, Takami H, Fukuoka K, Yamazaki K, Matsushita Y, Ohno M, Miyakita Y, Shibui S, Kubo A, Shuto T, Kocialkowski S, Yamanaka S, Mukasa A, Sasayama T, Mishima K, Maehara T, Kawahara N, Nagane M, Narita Y, Mano H, Ushijima T, Ichimura K.

Acta Neuropathol. 2017 Feb;133(2):321-324. doi: 10.1007/s00401-016-1664-8. Epub 2017 Jan 5. No abstract available.

PMID:
28058506
26.

Black hairy tongue after chemotherapy for malignant brain tumors.

Yamagishi Y, Maruyama K, Kobayashi K, Kume S, Sasaki N, Yokoya S, Saito K, Shiokawa Y, Nagane M.

Acta Neurochir (Wien). 2017 Jan;159(1):169-172. doi: 10.1007/s00701-016-3036-5. Epub 2016 Nov 23.

PMID:
27878617
27.

A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis.

Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI.

Neurooncol Pract. 2016 Dec;3(4):272-280. Epub 2016 Jan 7.

28.

Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.

ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Biol Ther. 2016 Oct 2;17(10):1107-1115.

29.

[10q LOH].

Saito K, Nagane M.

Nihon Rinsho. 2016 Sep;74 Suppl 7:126-131. Japanese. No abstract available.

PMID:
30634742
30.

Skeletal Muscle Oxygenation Measured by EPR Oximetry Using a Highly Sensitive Polymer-Encapsulated Paramagnetic Sensor.

Hou H, Khan N, Nagane M, Gohain S, Chen EY, Jarvis LA, Schaner PE, Williams BB, Flood AB, Swartz HM, Kuppusamy P.

Adv Exp Med Biol. 2016;923:351-357. doi: 10.1007/978-3-319-38810-6_46.

31.

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.

Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.

32.

Outcomes of chronic subdural hematoma with preexisting comorbidities causing disturbed consciousness.

Abe Y, Maruyama K, Yokoya S, Noguchi A, Sato E, Nagane M, Shiokawa Y.

J Neurosurg. 2017 Apr;126(4):1042-1046. doi: 10.3171/2016.3.JNS152957. Epub 2016 May 27.

PMID:
27231976
33.

The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).

Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H, Nagano O.

Cancer Res. 2016 May 15;76(10):2954-63. doi: 10.1158/0008-5472.CAN-15-2121. Epub 2016 Mar 15.

34.

Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.

Ichimura K, Fukushima S, Totoki Y, Matsushita Y, Otsuka A, Tomiyama A, Niwa T, Takami H, Nakamura T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K, Nakazato Y, Hosoda F, Narita Y, Shibui S, Yoshida A, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T, Kobayashi K, Shimizu S, Nagane M, Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K, Maehara T, Sugiyama K, Nakada M, Sakai K, Kanemura Y, Nonaka M, Asai A, Yokogami K, Takeshima H, Kawahara N, Takayama T, Yao M, Kato M, Nakamura H, Hama N, Sakai R, Ushijima T, Matsutani M, Shibata T, Nishikawa R; Intracranial Germ Cell Tumor Genome Analysis Consortium.

Acta Neuropathol. 2016 Jun;131(6):889-901. doi: 10.1007/s00401-016-1557-x. Epub 2016 Mar 8.

PMID:
26956871
35.

Evaluation of the relative biological effectiveness of spot-scanning proton irradiation in vitro.

Maeda K, Yasui H, Matsuura T, Yamamori T, Suzuki M, Nagane M, Nam JM, Inanami O, Shirato H.

J Radiat Res. 2016 Jun;57(3):307-11. doi: 10.1093/jrr/rrv101. Epub 2016 Feb 1.

36.

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.

Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.

Cancer Med. 2016 Mar;5(3):486-99. doi: 10.1002/cam4.614. Epub 2016 Jan 18.

37.

[Update Knowledge for Brain Tumors(3)Astrocytic Tumors].

Nagane M.

No Shinkei Geka. 2016 Jan;44(1):71-89. doi: 10.11477/mf.1436203210. Japanese. No abstract available.

PMID:
26771099
38.

Genomic characterization of primary central nervous system lymphoma.

Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H.

Acta Neuropathol. 2016 Jun;131(6):865-75. doi: 10.1007/s00401-016-1536-2. Epub 2016 Jan 12.

PMID:
26757737
39.

Inhibition of the mitochondrial fission protein dynamin-related protein 1 (Drp1) impairs mitochondrial fission and mitotic catastrophe after x-irradiation.

Yamamori T, Ike S, Bo T, Sasagawa T, Sakai Y, Suzuki M, Yamamoto K, Nagane M, Yasui H, Inanami O.

Mol Biol Cell. 2015 Dec 15;26(25):4607-17. doi: 10.1091/mbc.E15-03-0181. Epub 2015 Oct 14.

40.

ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.

Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, Paolocci N, Aon MA, Nagane M, Kuppusamy P, Steenbergen C, Gabrielson K.

Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1271-80. doi: 10.1152/ajpheart.00517.2014. Epub 2015 Aug 7.

41.

Dose-dense Temozolomide: Is It Still Promising?

Nagane M.

Neurol Med Chir (Tokyo). 2015;55 Suppl 1:38-49.

PMID:
26236801
42.

Requisite Role of Kv1.5 Channels in Coronary Metabolic Dilation.

Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK, Janota D, Oyewumi MO, Logan S, Lindner JR, Chilian WM.

Circ Res. 2015 Sep 11;117(7):612-621. doi: 10.1161/CIRCRESAHA.115.306642. Epub 2015 Jul 29.

43.

Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors.

Takami H, Fukushima S, Fukuoka K, Suzuki T, Yanagisawa T, Matsushita Y, Nakamura T, Arita H, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Kobayashi K, Nagane M, Iuchi T, Tamura K, Maehara T, Sugiyama K, Nakada M, Kanemura Y, Nonaka M, Yokogami K, Takeshima H, Narita Y, Shibui S, Nakazato Y, Nishikawa R, Ichimura K, Matsutani M.

J Neurooncol. 2015 Aug;124(1):23-32. doi: 10.1007/s11060-015-1809-y. Epub 2015 May 21.

PMID:
25994796
44.

Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma.

Keino H, Okada AA, Watanabe T, Echizen N, Inoue M, Takayama N, Nagane M.

Ocul Immunol Inflamm. 2016 Jun;24(3):268-73. doi: 10.3109/09273948.2014.1002568. Epub 2015 Mar 11.

PMID:
25760916
45.

Dose-dense temozolomide: is it still promising?

Nagane M.

Neurol Med Chir (Tokyo). 2015;55(1):38-49. doi: 10.2176/nmc.ra.2014-0277. Epub 2014 Dec 20. Review.

46.

Activation of eNOS in endothelial cells exposed to ionizing radiation involves components of the DNA damage response pathway.

Nagane M, Yasui H, Sakai Y, Yamamori T, Niwa K, Hattori Y, Kondo T, Inanami O.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):541-6. doi: 10.1016/j.bbrc.2014.12.002. Epub 2014 Dec 8.

47.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY.

J Clin Invest. 2014 Sep;124(9):3741-56. doi: 10.1172/JCI73093. Epub 2014 Jul 25.

48.

[Anti-angiogenic therapy for malignant glioma].

Nagane M.

Gan To Kagaku Ryoho. 2014 Feb;41(2):141-7. Review. Japanese.

PMID:
24743191
49.

JC virus inclusions in progressive multifocal leukoencephalopathy: scaffolding promyelocytic leukemia nuclear bodies grow with cell cycle transition through an S-to-G2-like state in enlarging oligodendrocyte nuclei.

Shishido-Hara Y, Yazawa T, Nagane M, Higuchi K, Abe-Suzuki S, Kurata M, Kitagawa M, Kamma H, Uchihara T.

J Neuropathol Exp Neurol. 2014 May;73(5):442-53. doi: 10.1097/NEN.0000000000000066.

50.

Neurosurgical simulation by interactive computer graphics on iPad.

Maruyama K, Kin T, Saito T, Suematsu S, Gomyo M, Noguchi A, Nagane M, Shiokawa Y.

Int J Comput Assist Radiol Surg. 2014 Nov;9(6):1073-8. doi: 10.1007/s11548-014-0993-0. Epub 2014 Mar 21.

PMID:
24651972

Supplemental Content

Loading ...
Support Center